These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 22354219)

  • 1. Aflibercept (eylea) for age-related macular degeneration.
    Med Lett Drugs Ther; 2012 Feb; 54(1383):9-10. PubMed ID: 22354219
    [No Abstract]   [Full Text] [Related]  

  • 2. Aflibercept for age-related macular degeneration: a game-changer or quiet addition?
    Browning DJ; Kaiser PK; Rosenfeld PJ; Stewart MW
    Am J Ophthalmol; 2012 Aug; 154(2):222-6. PubMed ID: 22813448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal aflibercept for neovascular age-related macular degeneration.
    Xu D; Kaiser PK
    Immunotherapy; 2013 Feb; 5(2):121-30. PubMed ID: 23413903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aflibercept-related sterile inflammation.
    Hahn P; Kim JE; Stinnett S; Chung MM; Dugel PU; Flynn HW; Huang SS; Sadda SR; Mahmoud TH;
    Ophthalmology; 2013 May; 120(5):1100-101.e1-5. PubMed ID: 23642742
    [No Abstract]   [Full Text] [Related]  

  • 5. Ziv-aflibercept (Zaltrap) for metastatic colorectal cancer.
    Med Lett Drugs Ther; 2013 Apr; 55(1415):e36. PubMed ID: 23836346
    [No Abstract]   [Full Text] [Related]  

  • 6. Regeneron focuses on age-related macular degeneration.
    Wolfson W
    Chem Biol; 2008 Apr; 15(4):303-4. PubMed ID: 18420133
    [No Abstract]   [Full Text] [Related]  

  • 7. Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF Trap - Regeneron, VEGF Trap (R1R2), VEGF Trap-Eye.
    Drugs R D; 2008; 9(4):261-9. PubMed ID: 18588357
    [No Abstract]   [Full Text] [Related]  

  • 8. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration.
    Nguyen QD; Shah SM; Hafiz G; Quinlan E; Sung J; Chu K; Cedarbaum JM; Campochiaro PA;
    Ophthalmology; 2006 Sep; 113(9):1522.e1-1522.e14. PubMed ID: 16876249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of the biological principles underlying the action of monoclonal antibody (mAb) and decoy receptor anti-VEGF agents--on the example of ranibizumab (anti-VEGF-A mAb) and aflibercept (decoy VEGFR1-2 receptor)].
    Golik P; Tońska K
    Klin Oczna; 2012; 114(1):79-83. PubMed ID: 22783753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wandering eye for RNAi.
    Rossi J; Zamore P; Kay MA
    Nat Med; 2008 Jun; 14(6):611. PubMed ID: 18535575
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term Outcomes of Aflibercept Treatment for Neovascular Age-related Macular Degeneration in a Clinical Setting.
    Călugăru D; Călugăru M
    Am J Ophthalmol; 2017 Feb; 174():185-186. PubMed ID: 28024647
    [No Abstract]   [Full Text] [Related]  

  • 12. Treat-and-Extend Therapy Using Aflibercept for Neovascular Age-Related Macular Degeneration: A Prospective Clinical Trial.
    Călugăru D; Călugăru M
    Am J Ophthalmol; 2017 Oct; 182():204-205. PubMed ID: 28800905
    [No Abstract]   [Full Text] [Related]  

  • 13. [Pharmacological therapy for age-related macular degeneration. Current developments and perspectives].
    Holz FG; Miller DW
    Ophthalmologe; 2003 Feb; 100(2):97-103. PubMed ID: 12589452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Future methods of treatment in age related macular degeneration].
    Turlea C
    Oftalmologia; 2012; 56(1):30-5. PubMed ID: 22888684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
    Ziemssen F; Heiduschka P; Schraermeyer U;
    Retina; 2007 Oct; 27(8):1154-6; author reply 1156-8. PubMed ID: 18040264
    [No Abstract]   [Full Text] [Related]  

  • 16. [Unspecific effects of certain siRNA molecules used in the treatment of age related macular degeneration].
    Ebbesen M; Bek T; Pedersen FS; Jensen TG
    Ugeskr Laeger; 2010 Sep; 172(36):2457-9. PubMed ID: 20825735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. When should anti-vascular endothelial growth factor treatment be stopped in age-related macular degeneration?
    Gaudric A; Cohen SY
    Am J Ophthalmol; 2010 Jan; 149(1):4-6. PubMed ID: 20103036
    [No Abstract]   [Full Text] [Related]  

  • 18. Technology evaluation: pegaptanib, Eyetech/Pfizer.
    Vinores SA
    Curr Opin Mol Ther; 2003 Dec; 5(6):673-9. PubMed ID: 14755895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Safety aspect of age macular degeneration treatment].
    Zyrianov SK; Belousov IuB
    Vestn Oftalmol; 2012; 128(4):75-7. PubMed ID: 22994114
    [No Abstract]   [Full Text] [Related]  

  • 20. [Treatment of neovascular age-related macular degeneration with Ranibizumab/Lucentis].
    Michels S; Rosenfeld PJ
    Klin Monbl Augenheilkd; 2005 Jun; 222(6):480-4. PubMed ID: 15973626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.